Scharf Martin B
The Center for Research in Sleep Disorders, 1275 Kemper Road Cincinnati, OH 45246-3901, USA.
Expert Rev Neurother. 2006 Aug;6(8):1139-46. doi: 10.1586/14737175.6.8.1139.
Sodium oxybate (Xyrem), also known as gamma-hydroxybutyric acid, is the only therapeutic specifically approved in the USA for the treatment of cataplexy in narcolepsy. The US FDA has recently expanded its indication to include excessive daytime sleepiness associated with narcolepsy. In contrast to the antidepressants and stimulants commonly used to treat the disorder, sodium oxybate is the only compound that addresses both sets of symptoms and, when used properly, is less likely to lead to the development of tolerance and other undesirable side effects. In this review, the results of clinical trials and the place of sodium oxybate in narcolepsy treatment are discussed.
羟丁酸钠(Xyrem),也被称为γ-羟基丁酸,是美国唯一专门批准用于治疗发作性睡病猝倒症的药物。美国食品药品监督管理局(FDA)最近扩大了其适应症,将与发作性睡病相关的日间过度嗜睡也纳入其中。与常用于治疗该疾病的抗抑郁药和兴奋剂不同,羟丁酸钠是唯一能同时解决这两组症状的化合物,并且如果使用得当,产生耐受性和其他不良副作用的可能性较小。在本综述中,将讨论临床试验结果以及羟丁酸钠在发作性睡病治疗中的地位。